DSM, Crucell to expand PER.C6 technology licensing collaboration (Forbes)

AMSTERDAM (AFX) - Crucell NV and Royal DSM NV unit DSM Biologics said they will strengthen and expand their existing collaboration on Crucell's PER.C6 protein and monoclonal antibody licensing technology.